Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spatial and multi-omic profiling reveals pericyte-derived CCL19 as a key prognostic factor in CNS lymphoma.

HemaSphere·2026
Same author

The Phase Ib VenObi CNS Study: Chemotherapy-Free Treatment with Venetoclax and Obinutuzumab for Relapsed/Refractory Primary Large B-Cell Lymphoma of the Central Nervous System.

Cancers·2026
Same author

Cracking the POD24 code in follicular lymphoma.

Blood·2025
Same author

Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention.

Cancer cell·2025
Same author

The effect of ibrutinib on the myeloid cell compartment in CNS lymphoma.

Leukemia·2025
Same author

Intraoperative classification of CNS lymphoma and glioblastoma by AI-based analysis of Stimulated Raman Histology (SRH).

Brain & spine·2025

Related Experiment Video

Updated: Jan 5, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

7.1K

Capturing Tumor Heterogeneity and Clonal Evolution by Circulating Tumor DNA Profiling.

Florian Scherer1

  • 1Department of Hematology, Oncology, and Stem Cell Transplantation, University Medical Center Freiburg, Albert-Ludwigs-University, Hugstetter Straße 55, 79106, Freiburg, Germany. florian.scherer@uniklinik-freiburg.de.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|October 13, 2019
PubMed
Summary
This summary is machine-generated.

Tumor heterogeneity impacts cancer management. Noninvasive circulating tumor DNA (ctDNA) profiling offers a comprehensive alternative to tissue genotyping for characterizing tumor genetics and guiding patient treatment.

Keywords:
Circulating tumor DNAClonal evolutionHigh-throughput sequencingNoninvasive relapse detectionTherapy-resistant subclonesTumor heterogeneity

More Related Videos

Target Cell Pre-enrichment and Whole Genome Amplification for Single Cell Downstream Characterization
10:12

Target Cell Pre-enrichment and Whole Genome Amplification for Single Cell Downstream Characterization

Published on: May 15, 2018

9.4K
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

9.1K

Related Experiment Videos

Last Updated: Jan 5, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

7.1K
Target Cell Pre-enrichment and Whole Genome Amplification for Single Cell Downstream Characterization
10:12

Target Cell Pre-enrichment and Whole Genome Amplification for Single Cell Downstream Characterization

Published on: May 15, 2018

9.4K
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

9.1K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Malignancies exhibit significant molecular heterogeneity, influencing clinical cancer management.
  • Understanding tumor heterogeneity is crucial for personalized therapy, risk stratification, and identifying resistance mechanisms.

Purpose of the Study:

  • To explore the role of noninvasive genotyping and circulating tumor DNA (ctDNA) profiling.
  • To characterize tumor heterogeneity and its clinical relevance in hematologic and solid cancers.

Main Methods:

  • Review of noninvasive genotyping techniques.
  • Analysis of ctDNA profiling for genetic and epigenetic assessment.
  • Comparison with traditional tumor tissue genotyping.

Main Results:

  • Tissue sampling for genotyping is often insufficient and carries surgical risks.
  • ctDNA profiling provides a noninvasive, quantitative method for comprehensive genetic landscape assessment.
  • ctDNA enables monitoring of clonal evolution during treatment and disease progression.

Conclusions:

  • Noninvasive ctDNA profiling is a powerful tool for robustly characterizing tumor heterogeneity.
  • This approach has significant implications for the clinical management of both hematologic and solid cancers.